A Phase 1/2, Prospective, Randomized, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 10-Valent Pneumococcal Conjugate Vaccine in Healthy Young Adults, Toddlers, and Infants
Phase of Trial: Phase I/II
Latest Information Update: 29 Dec 2016
At a glance
- Drugs SIILPCV10 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions
- 22 Dec 2016 Status changed from active, no longer recruiting to completed.
- 13 Sep 2016 Planned End Date changed from 1 May 2016 to 1 Oct 2016.
- 13 Sep 2016 Planned primary completion date changed from 1 May 2016 to 1 Oct 2016.